Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Endocrine Journal

Volumn 62, Issue 7, 2015, Pages 593-603

  Seino, Yutaka ^a   Kaku, Kohei ^b   Inagaki, Nobuya ^c   Haneda, Masakazu ^d   Sasaki, Takashi ^e   Fukatsu, Atsushi ^f   Ubukata, Michito ^g   Sakai, Soichi ^g   Samukawa, Yoshishige ^g  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Yachiyo Hospital   (Japan)

^g TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Long term; Luseogliflozin; Monotherapy; Sodium glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KETONE BODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUSEOGLIFLOZIN; NITROGEN; TRIACYLGLYCEROL; UREA; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SORBITOL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOCRIT; HUMAN; HYPOGLYCEMIA; INTERMETHOD COMPARISON; JAPANESE (PEOPLE); KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POLLAKISURIA; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; JAPAN; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; SORBITOL; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84938319426     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ15-0097     Document Type: Article

References (20)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th edn. Available from: http://www.idf.org/diabetesatlas/[Last accessed 2nd February 2015]
2. Grundy SM (2008) Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28: 629-636.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364-1379.
4. Ahren B (2012) DPP-4 inhibition and islet function. J Diabetes Investig 3: 3-10.
5. Seino Y, Yabe D (2013) Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 4: 108-130.
6. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, et al. (2014) Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin 30: 1231–1244.
7. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, et al. (2014) Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 30: 1245–1255.
8. Guideline for clinical evaluation of oral hypoglycemic agents. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2010. Available from: http://www.pmda. go.jp/kijunsakusei/guideline.html [Last accessed 2nd February 2015]
9. ICH harmonised tripartite guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1994. Available from: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html [Last accessed 2nd February 2015]
10. Kashiwagi A, Kasuga M, Araki E, Ota Y, Hanafusa T, et al. (2012) International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 3: 8–10.
11. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, et al. (2014) Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, Phase II study. Curr Med Res Opin 30: 1219-1230
12. Odawara M, Kadowaki T, Tajima N, Nishii M, Taniguchi T, et al. (2011) Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetol Int 2: 94-105.
13. Abdul-Ghani MA, DeFronzo RA, Norton L (2013) Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 62: 3324-3328.
14. Canagliflozin (Invokana®): prescribing information. Available from: http://www.invokanahcp.com/prescribing-information.pdf/
15. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, et al. (2013) Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 473-478.
16. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, et al. (2013) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 479-484.
17. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.
18. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M (2010) Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: Effects on glycaemic control and body weight. Diabetes Obes Metab 12: 510-516.
19. Kohan DE, Fioretto P, Tang W, List JF (2014) Longterm study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962-971.
20. Haneda M, Seino Y, Sasaki T, Fukatsu A, Samukawa Y, et al. (2012) Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control in Japanese type 2 diabetic subjects with renal impairment. 48th European Association for the Study of Diabetes (EASD) Annual Meeting, October 1-5, 2012. Berlin, Germany. (Abstract)